[儿童肾母细胞瘤综合治疗中的辅助化疗]

[Adjuvant chemotherapy in the combined modality therapy of nephroblastoma in children].

作者信息

Badalian G Kh, Lebedev V I

出版信息

Vopr Onkol. 1988;34(11):1355-9.

Abstract

The paper discusses the end results of complex treatment of 31 children comprising preoperative therapy, nephrectomy and adjuvant chemotherapy. Two-year survival was 64.5% and two-year recurrence-free survival--48.4%. Adjuvant chemotherapy (vincristine, dactinomycin and adriamycin) was given to 25 cases. Complete treatment consisting of 4 courses of adjuvant chemotherapy was carried out in 12 patients only, tumor progression and toxic hepatitis being the most frequent causes of adjuvant treatment suspension. Survival was shown to depend on such prognostic factors as the efficacy of preoperative chemotherapy, stage and morphological pattern of tumor rather than adjuvant chemotherapy duration. Therefore, a short course of adjuvant chemotherapy may be recommended for localized nephroblastoma in pediatric patients.

摘要

本文讨论了31例儿童复杂治疗的最终结果，包括术前治疗、肾切除术和辅助化疗。两年生存率为64.5%，两年无复发生存率为48.4%。25例患者接受了辅助化疗（长春新碱、放线菌素D和阿霉素）。仅12例患者完成了由4个疗程辅助化疗组成的完整治疗，肿瘤进展和中毒性肝炎是辅助治疗中断的最常见原因。结果表明，生存率取决于术前化疗的疗效、肿瘤分期和形态学类型等预后因素，而非辅助化疗的持续时间。因此，对于小儿局限性肾母细胞瘤，可推荐短疗程辅助化疗。